Prostate Cancer, Early, Recurrent Clinical Trials

A listing of Prostate Cancer, Early, Recurrent medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

California

Radiological Sciences David Geffen School of Medecine at UCLA
Los Angeles California 90024

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Illinois

The University of Chicago
Chicago Illinois 60637

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Indiana

Indiana University
Indianapolis Indiana 46202

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Maryland

Johns Hopkins University
Baltimore Maryland 21205

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Michigan

William Beaumont Hospital
Royal Oak Michigan 48073

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Tennessee

Vanderbilt University Medical Center
Nashville, Tennessee 37232

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Texas

University of Texas Southwestern Medical Center
Dallas Texas 75390

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Canada

London Health Sciences Centre
London International N6A 5W9

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Sunnybrook Health Sciences Centre
Toronto International M4N 3M5

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Germany

Heidelberg University
Heidelberg International 69120

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Cologne University Hospital
Köln International 50937

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Netherlands

Radboud University Medical Center
Nijmegen International 6500HB

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Spain

ResoFus Alomar
Barcelona International 08029

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.

Clinica Universidad de Navarra
Pamplona International

TACT (TULSA-PRO® Ablation Clinical Trial ) is an MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer. Highly reputable research institutions across the US, Canada and Europe are participating in this multi-center study. The study will enroll 110 patients with low to intermediate risk, locally confined prostate cancer.